ARA-290
Cibinetide — erythropoietin-derived peptide for nerve repair, neuropathic pain, and systemic anti-inflammation.
Danh mục
Healing & Recovery
Tần suất
Daily
Nghiên cứu
Phase 2 Clinical TrialsARA-290 Là Gì?
ARA-290 (also known as Cibinetide) is a cyclic peptide derived from the innate repair receptor-binding region of erythropoietin (EPO). It is designed to activate the tissue-protective receptor (innate repair receptor) without the erythropoiesis (red blood cell production) effects of full EPO — capturing EPO's protective benefits without the risk of blood thickening.
ARA-290 was developed specifically for neuropathic pain and peripheral nerve repair. Phase 2 clinical trials in patients with sarcoidosis-related neuropathy demonstrated significant reductions in neuropathic pain and improvements in nerve fiber density — meaning it actually regenerated damaged nerve fibers.
This makes ARA-290 unique — it is one of the only compounds with clinical evidence for actual peripheral nerve regeneration, not just pain management. It's used by users with diabetic neuropathy, chemotherapy-induced neuropathy, nerve injuries, and chronic neuropathic pain conditions.
Cơ Chế Hoạt Động
Innate Repair Receptor Activation: ARA-290 binds to the tissue-protective (innate repair) receptor, which is separate from the EPO receptor responsible for red blood cell production. This activates repair and anti-inflammatory pathways in neurons and other tissues.
Neurotrophic Factor Upregulation: ARA-290 increases expression of BDNF, NGF, and other neurotrophic factors that support nerve survival and regeneration.
Anti-Apoptotic Signaling: ARA-290 activates JAK2/STAT3 and PI3K/Akt pathways, which protect neurons from programmed cell death.
Lợi Ích
- Peripheral nerve regeneration (clinical evidence)
- Significant neuropathic pain reduction
- Diabetic neuropathy treatment
- Systemic anti-inflammatory effects
- Organ protection (heart, kidney)
- Improved insulin sensitivity
- Metabolic benefits in diabetic models
Quy Trình Liều Lượng
| Giai đoạn | Liều lượng | Tần suất | Thời gian |
|---|---|---|---|
| Neuropathy Protocol | 4mg | Once daily SC | 4–8 weeks |
| Pain Management | 2–4mg | Once daily | Ongoing as needed |
Luôn bắt đầu với liều thấp nhất có hiệu quả và tăng dần.
Tác Dụng Phụ
Phổ biến
- ⚠Injection site reactions
- ⚠Mild headache
- ⚠Fatigue in first week
Hiếm gặp
- •Dizziness
- •Elevated blood pressure (monitor)
Ai Không Nên Dùng ARA-290
- ✕Active cancer
- ✕History of thromboembolic disease (consult physician)
- ✕Pregnancy or breastfeeding
- ✕Severe hypertension
Điều Bạn Có Thể Mong Đợi
Some users report early pain reduction. Nerve regeneration begins but is not yet felt.
Significant pain reduction in most users. Tingling and burning sensations decrease.
Clinical trials showed maximum nerve fiber density improvements at 8 weeks. Sustained pain relief.
Long-term maintenance dosing may be needed for chronic conditions. Nerve regeneration continues.
Hỏi & Đáp
Q: Is ARA-290 the same as EPO (erythropoietin)?
A: No. ARA-290 is derived from a small region of the EPO molecule and specifically activates only the tissue-protective receptor. It does NOT stimulate red blood cell production or carry EPO's blood-thickening risks.
Q: Can ARA-290 help with diabetic neuropathy?
A: Yes — this is one of its primary studied applications. Phase 2 trials showed significant improvements in both small fiber neuropathy symptoms and actual nerve fiber density in diabetic patients.
Mua ARA-290 Ở Đâu Tại Việt Nam
Xem danh sách nhà cung cấp đã được cộng đồng xác minh với COA và giao hàng lạnh đến Việt Nam.